Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05393388 · ClinicalTrials.gov registry record
Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
A clinical trial of Alzheimer Disease and Cognitive Decline, sponsored by University of Pennsylvania.
- Active
- Registry status
- 111
- Enrollment target
- 1
- Study location
NCT05393388 is a study of Alzheimer Disease and Cognitive Decline that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 111 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05393388, a study of Alzheimer Disease and Cognitive Decline, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
We will conduct a Tau PET scan in cognitively normal older adults, enrolled in the Aging Brain Cohort Dedicated to Diversity Study (ABCD2-Tau) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).Study duration will generally be a one-day study visit for PET imaging, but all subjects will be followed annually as part of their participation in the ABCD2 study. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of preclinical Alzheimer's Disease.
Conditions Studied
Interventions
- DRUG [18F]AV-1451
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Penn Memory Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2022-07-06 |
| Est. Completion | 2027-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05393388
The ClinicalTrials.gov registry entry for NCT05393388 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [18F]AV-1451 is the first listed.
NCT05393388 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05393388 about?
NCT05393388 is a clinical study titled "Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study". We will conduct a Tau PET scan in cognitively normal older adults, enrolled in the Aging Brain Cohort Dedicated to Diversity Study (ABCD2-Tau) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).Study duration will generally be a one-day study visit...
What is the current status of trial NCT05393388?
This trial is currently active not recruiting. The enrollment target is 111 participants. The study started on 2022-07-06. Estimated completion is 2027-05.
What conditions does trial NCT05393388 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Decline.
What interventions are being tested in trial NCT05393388?
The interventions under investigation include: [18F]AV-1451 (DRUG).
Who is sponsoring clinical trial NCT05393388?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05393388 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.